Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dual-target CAR-T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04889716
What this trial is testing

CAR-T Followed by Bispecific Antibodies

Who this might be right for
Large B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma
Abramson Cancer Center at Penn Medicine 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05091541
What this trial is testing

CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Who this might be right for
B-cell Non-Hodgkin's Lymphoma
Nanjing IASO Biotechnology Co., Ltd. 125
Testing effectiveness (Phase 2)Looking for participantsNCT05850234
What this trial is testing

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AstraZeneca 232
Early research (Phase 1)Temporarily pausedNCT04650451
What this trial is testing

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Who this might be right for
HER-2 Gene AmplificationHER2-positive Gastric CancerHER2-positive Breast Cancer+2 more
Bellicum Pharmaceuticals 220
Early research (Phase 1)Looking for participantsNCT07139509
What this trial is testing

Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma(MM)
Xi'an No.3 Hospital 18
Large-scale testing (Phase 3)Looking for participantsNCT07188558
What this trial is testing

Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Who this might be right for
Large B-cell LymphomaLymphoma, B-CellRelapsed Non-Hodgkin Lymphoma+6 more
Lyell Immunopharma, Inc. 400
Very early researchNot Yet RecruitingNCT07201727
What this trial is testing

CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
AML - Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China 10
Early research (Phase 1)UnknownNCT05976906
What this trial is testing

Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Zhejiang University 36
Early research (Phase 1)Looking for participantsNCT07333261
What this trial is testing

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Susan Bal 25
Very early researchUnknownNCT05225831
What this trial is testing

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
CD19+ and CD 22+ B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 100
Very early researchUnknownNCT04617704
What this trial is testing

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 15
Early research (Phase 1)Looking for participantsNCT05477927
What this trial is testing

Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases

Who this might be right for
Malignant Peritoneal EffusionMalignant AscitesSerous Cavity Metastatises+1 more
Sichuan University 40
Very early researchNot Yet RecruitingNCT07077330
What this trial is testing

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Who this might be right for
Relapsed or Refractory Plasma Cell Neoplasms
Chinese PLA General Hospital 20
Early research (Phase 1)Looking for participantsNCT07073547
What this trial is testing

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Who this might be right for
Multiple Myeloma
AstraZeneca 40
Very early researchUnknownNCT04303247
What this trial is testing

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Who this might be right for
B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Xinqiao Hospital of Chongqing 30
Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Large-scale testing (Phase 3)Looking for participantsNCT07391657
What this trial is testing

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Who this might be right for
Relapsed Refractory Multiple Myeloma
AstraZeneca 508
Early research (Phase 1)Looking for participantsNCT06880354
What this trial is testing

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China 37
Large-scale testing (Phase 3)Looking for participantsNCT07764978
What this trial is testing

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Who this might be right for
Newly Diagnosed Multiple Myeloma
AstraZeneca 750
Early research (Phase 1)Ended earlyNCT05169489
What this trial is testing

BbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals 15
Next Page